TOBACCO SMOKING EPIDEMIOLOGY AND EFFECTIVE NICOTINE ADDICTION CESSATION METHODS
DOI:
https://doi.org/10.56782/pps.28Keywords:
addiction, nicotine, cytisine, varenicline, bupropionAbstract
Smoking tobacco products in Poland and in the world is a significant epidemiological and health problem. Leading to addiction to nicotine, smokers absorb many toxic and carcinogenic substances and suffer from a number of tobacco-related diseases that often require complex medical interventions. Due to the nature of the addiction, smoking cessation is difficult. On the pharmaceutical market in Poland are present pharmaceutical products that can help in the fight against nicotine addiction. These products contain as active substances nicotine, cytisine, varenicline or bupropion. The review aims to discuss current state of knowledge on nicotine addiction in Poland, present active substance that can help against nicotine addiction and present their clinical efficacy and safety.
Downloads
References
Trząsalska A., Staszyńska M., Krassowska U. Raport z ogólnopolskiego badania ankietowego na temat postaw wobec palenia tytoniu, Kantar Public dla Głównego Inspektoratu Sanitarnego; 2017.
WUM. Warszawski Uniwersytet Medyczny | Kampania Nie Spalaj się [Internet], 2018 [cited 12 Mar 2019].
Samochowiec J., Rogoziński D., Hajduk A., Skrypińska A., Arentowicz G. Diagnostyka, mechanizm uzależnienia i metody leczenia uzależnienia od nikotyny. Alkoholizm i Narkomania, Alkohol Narkom, 2001, 14, 323–340.
Yildiz D. Nicotine, its metabolism and an overview of its biological effects, Toxicon Off J Int Soc Toxinology, 2004, 43, 619–632. DOI: https://doi.org/10.1016/j.toxicon.2004.01.017
Molyneux A., Králíková E., Himmerová V. ABC of smoking cessation. Nicotine replacement therapy, Cas Lek Cesk, 2004, 143, 781–783.
Schnoll RA., Goelz PM., Veluz – Wilkins A., Blazekovic S., Powers L., Leone FT., Gariti P., Wileyto EP., Hitsman B. Long–term nicotine replacement therapy: a randomized clinical trial, JAMA Intern Med, 2015, 175, 504–511. DOI: https://doi.org/10.1001/jamainternmed.2014.8313
Ellerbeck EF., Nollen N., Hutcheson TD., Phadnis M., Fitzgerald SA., Vacek J., Sharpe MR., Salzman GA., Richter KP. Effect of Long – term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial, JAMA Netw Open, 2018, 1, e181843. DOI: https://doi.org/10.1001/jamanetworkopen.2018.1843
Koegelenberg CFN., Noor F., Bateman ED., van Zyl–Smit RN., Bruning A., O’Brien JA., Smith C., Abdool–Gaffar MS., Emanuel S., Esterhuizen TM., Irusen EM. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial, JAMA, 2014, 312, 155–161. DOI: https://doi.org/10.1001/jama.2014.7195
Scherphof CS., van den Eijnden RJJM., Engels RCME., Vollebergh WAM. Long–term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial, Drug Alcohol Depend, 2014, 140, 217–220. DOI: https://doi.org/10.1016/j.drugalcdep.2014.04.007
Mayer B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self – experiments in the nineteenth century, Arch Toxicol, 2014, 88, 5–7. DOI: https://doi.org/10.1007/s00204-013-1127-0
Moore D., Aveyard P., Connock M., Wang D., Fry–Smith A., Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta–analysis, BMJ, 2009, 338, b1024. DOI: https://doi.org/10.1136/bmj.b1024
Lavelle C., Birek C., Scott DA. Are nicotine replacement strategies to facilitate smoking cessation safe?, J Can Dent Assoc, 2003, 69, 592–597.
Osadchy A., Kazmin A., Koren G. Nicotine replacement therapy during pregnancy: recommended or not recommended?, J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC, 2009, 31, 744–747. DOI: https://doi.org/10.1016/S1701-2163(16)34281-5
Hajek P., Phillips–Waller A., Przulj D., Pesola F., Myers Smith K., Bisal N., Li J., Parrott S., Sasieni P., Dawkins L., Ross L., Goniewicz M., Wu Q., McRobbie HJ. A Randomized Trial of E–Cigarettes versus Nicotine–Replacement Therapy, N Engl J Med, 2019, 380, 629–637. DOI: https://doi.org/10.1056/NEJMoa1808779
Gopalakrishnan M., Monteggia LM., Anderson DJ., Molinari EJ., Piattoni–Kaplan M., Donnelly–Roberts D., Arneric SP., Sullivan JP. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor, J Pharmacol Exp Ther, 1996, 276, 289–297.
Sloan JW., Martin WR., Bostwick M., Hook R., Wala E. The comparative binding characteristics of nicotinic ligands and their pharmacology, Pharmacol Biochem Behav, 1988, 30, 255–267. DOI: https://doi.org/10.1016/0091-3057(88)90454-6
Coe JW., Brooks PR., Vetelino MG., Wirtz MC., Arnold EP., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation, J Med Chem, 2005, 48, 3474–3477. DOI: https://doi.org/10.1021/jm050069n
Zatoński W., Zatoński M. Cytisine versus nicotine for smoking cessation, N Engl J Med, 2015, 372, 1072. DOI: https://doi.org/10.1056/NEJMc1500342
Walker N., Howe C., Glover M., McRobbie H., Barnes J., Nosa V., Parag V., Bassett B., Bullen C. Cytisine versus nicotine for smoking cessation, N Engl J Med, 2014, 371, 2353–2362. DOI: https://doi.org/10.1056/NEJMoa1407764
West R., Zatonski W., Cedzynska M., Lewandowska D., Pazik J., Aveyard P., Stapleton J. Placebo – controlled trial of cytisine for smoking cessation, N Engl J Med, 2011, 365, 1193–1200. DOI: https://doi.org/10.1056/NEJMoa1102035
Zatonski W., Cedzynska M., Tutka P., West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation, Tob Control, 2006, 15, 481–484. DOI: https://doi.org/10.1136/tc.2006.016097
Rigotti NA. Cytisine — A Tobacco Treatment Hiding in Plain Sight, N Engl J Med, 2014, 371, 2429–2430. DOI: https://doi.org/10.1056/NEJMe1412313
Cahill K., Stead LF., Lancaster T. Nicotine receptor partial agonists for smoking cessation, Cochrane Database Syst Rev, 2012, CD006103. DOI: https://doi.org/10.1002/14651858.CD006103.pub6
McCarthy DE., Versella M. Quitting Failure and Success With and Without Using Medication: Latent Classes of Abstinence and Adherence to Nicotine Monotherapy, Combination Therapy, and Varenicline, Nicotine Tob Res Off J Soc Res Nicotine Tob, 2018. DOI: https://doi.org/10.1093/ntr/nty157
Singh D., Saadabadi A. Varenicline, StatPearls, Treasure Island (FL): StatPearls Publishing; 2018.
Fouz–Rosón N., Montemayor–Rubio T., Almadana–Pacheco V., Montserrat–García S., Gómez–Bastero AP., Romero–Muñoz C., Polo–Padillo J. Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial, Addict Abingdon Engl, 2017, 112, 1610– 1619. DOI: https://doi.org/10.1111/add.13855
Ebbert JO., Hughes JR., West RJ., Rennard SI., Russ C., McRae TD., Treadow J., Yu C–R., Dutro MP., Park PW. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial, JAMA, 2015, 313, 687–694. DOI: https://doi.org/10.1001/jama.2015.280
Baker TB., Piper ME., Stein JH., Smith SS., Bolt DM., Fraser DL., Fiore MC. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial, JAMA, 2016, 315, 371–379. DOI: https://doi.org/10.1001/jama.2015.19284
Rohsenow DJ., Tidey JW., Martin RA., Colby SM., Swift RM., Leggio L., Monti PM. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms, Addict Abingdon Engl, 2017, 112, 1808–1820. DOI: https://doi.org/10.1111/add.13861
Tulloch HE., Pipe AL., Els C., Clyde MJ., Reid RD. Flexible, dual–form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial, BMC Med, 2016, 14, 80. DOI: https://doi.org/10.1186/s12916-016-0626-2
Rollema H., Hurst RS. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data, Psychopharmacology (Berl), 2018, 235, 2479–2505. DOI: https://doi.org/10.1007/s00213-018-4921-9
Goulden R., Nguyen QD., Azoulay L. Risk of Bias in Study of Varenicline and Cardiovascular Outcomes, Am J Respir Crit Care Med, 2018, 198, 690–691. DOI: https://doi.org/10.1164/rccm.201803-0423LE
Klemperer EM., Hughes JR., Naud S. Study characteristics influencethe efficacy of substance abuse treatments: A meta–analysis of medications for smoking cessation, Nicotine Tob Res Off J Soc Res Nicotine Tob, 2018. DOI: https://doi.org/10.1093/ntr/nty225
Huecker MR., Saadabadi A. Bupropion, StatPearls, Treasure Island (FL): StatPearls Publishing; 2019.
Planer D., Lev I., Elitzur Y., Sharon N., Ouzan E., Pugatsch T., Chasid M., Rom M., Lotan C. Bupropion for smoking cessation in patients with acute coronary syndrome, Arch Intern Med, 2011, 171, 1055–1060. DOI: https://doi.org/10.1001/archinternmed.2011.72
Hays JT., Hurt RD., Decker PA., Croghan IT., Offord KP., Patten CA. A randomized, controlled trial of bupropion sustained – release for preventing tobacco relapse in recovering alcoholics, Nicotine Tob Res Off J Soc Res Nicotine Tob, 2009, 11, 859–867. DOI: https://doi.org/10.1093/ntr/ntp077
Schnoll RA., Martinez E., Tatum KL., Weber DM., Kuzla N., Glass M., Ridge JA., Langer C., Miyamoto C., Wileyto EP., Leone F. A bupropion smoking cessation clinical trial for cancer patients, Cancer Causes Control CCC, 2010, 21, 811–820. DOI: https://doi.org/10.1007/s10552-010-9507-8
Sheng L., Tang Y., Jiang Z., Yao C., Gao J., Xu G–Z., Tong X. Sustained–release bupropion for smoking cessation in a Chinese sample: a double–blind, placebo–controlled, randomized trial, Nicotine Tob Res Off J Soc Res Nicotine Tob, 2013, 15, 320–325. DOI: https://doi.org/10.1093/ntr/nts124
Cox LS., Nollen NL., Mayo MS., Choi WS., Faseru B., Benowitz NL., Tyndale RF., Okuyemi KS., Ahluwalia JS. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial, J Natl Cancer Inst, 2012, 104, 290–298. DOI: https://doi.org/10.1093/jnci/djr513
Zellweger J–P., Boelcskei PL., Carrozzi L., Sepper R., Sweet R., Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals, Am J Health Behav, 2005, 29, 240–249. DOI: https://doi.org/10.5993/AJHB.29.3.5
Hatsukami DK., Rennard S., Patel MK., Kotlyar M., Malcolm R., Nides MA., Dozier G., Bars MP., Jamerson BD. Effects of sustained – release bupropion among persons interested in reducing but not quitting smoking, Am J Med, 2004, 116, 151–157. DOI: https://doi.org/10.1016/j.amjmed.2003.07.018
Evins AE., Culhane MA., Alpert JE., Pava J., Liese BS., Farabaugh A., Fava M. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders, J Clin Psychopharmacol, 2008, 28, 660–666. DOI: https://doi.org/10.1097/JCP.0b013e31818ad7d6
Ebbert JO., Croghan IT., Sood A., Schroeder DR., Hays JT., Hurt RD. Varenicline and bupropion sustained–release combination therapy for smoking cessation, Nicotine Tob Res Off J Soc Res Nicotine Tob, 2009, 11, 234–239. DOI: https://doi.org/10.1093/ntr/ntn031
Zhu J., Coppens RP., Rabinovich NE., Gilbert DG. Effects of bupropion sustained release on task–related EEG alpha activity in smokers: Individual differences in drug response, Exp Clin Psychopharmacol, 2017, 25, 41–49. DOI: https://doi.org/10.1037/pha0000109
Anthenelli RM., Benowitz NL., West R., St Aubin L., McRae T., Lawrence D., Ascher J., Russ C., Krishen A., Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double – blind, randomised, placebo–controlled clinical trial, Lancet Lond Engl, 2016, 387, 2507–2520. DOI: https://doi.org/10.1016/S0140-6736(16)30272-0
Walker N., Smith B., Barnes J., Verbiest M., Kurdziel T., Parag V., Pokhrel S., Bullen C. Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non – inferiority trial, Addict Abingdon Engl, 2019, 114, 344–352. DOI: https://doi.org/10.1111/add.14449
Thomas D., Farrell M., McRobbie H., Tutka P., Petrie D., West R., etal. The effectiveness, safety and cost–effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: astudy protocol for a randomized controlled non–inferiority trial, Addict Abingdon Engl, 2018. DOI: https://doi.org/10.1111/add.14541
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
